Lon Garber’s Excellent Adventure: facing Gollum, P.T. & Paul Simon with R2D2
Lon Garber It all began in Africa with a pain in my backside. My wife, Val, jokingly called it payback time since I’d been a pain in her backside for 37 years. The [...]
LRG Research Team members publish results of imatinib combination study
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
2013 GI ASCO GIST summary
This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
Understanding How GISTs Develop Enables Discovery of New Therapies
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
Imatinib Plasma Levels Revisited – An editorial post by Jerry Call
Since we have gotten a number of questions about Gleevec (imatinib) plasma levels and testing, I think it’s time to revisit the subject, especially for newer members. Since this is a very complex subject, this may take a few emails and a few days.
Sutent – What to Expect When You Begin
Sutent is the second-line approved treatment for Gastrointestinal Stromal Tumor and is prescribed when treatment with the first-line drug, Gleevec (Imatinib) is no longer effective or cannot be tolerated. The two drugs work differently, so [...]
Phase II SARC-022 IGF-1R Trial Currently Recruiting and Planning to Add New Sites
The Sarcoma Alliance for Research through Collaboration (SARC) in partnership with the National Cancer Institute (NCI) is currently recruiting patients for its Phase II trial (SARC-022) of Linsitinib (OSI-906), an IGF-1R inhibitor. Linsitinib is targeted [...]
Sutent Treatment Use Trial Results
Patients with GIST who received sunitinib using a flexible dose approach to manage adverse events remained on treatment longer than those who received the strict dose/schedule and exhibited better clinical outcomes (longer time to tumor progression and longer overall survival).
Stivarga Side Effects
Stivarga comes in 40 mg tablets. Once opened, it must be used within 28 days. Stivarga must be stored in the bottle that it comes in, the desiccant must remain in the bottle; keep bottle tightly sealed. Do not store in a daily or weekly pill box.
Clinical Trials Database Explained
You may not have noticed, but the clinical trials section of the website has changed dramatically in the last month. This section of the website is now database-driven and has a lot more information.